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Abstract
Background:  Some alterations of the lipoprotein profile have been associated with
cerebrovascular disease. Recently, it has been suggested that cerebrovascular disease might play a
role in the pathogenesis of both vascular dementia (VD) and Alzheimer's disease (AD).
Nevertheless, the possible association of dyslipidemias with VD or AD is still a controversial issue.
Methods: We investigated the lipoprotein profile in 100 older patients with vascular dementia
(VD; n°: 60) or Late Onset Alzheimer's Disease (LOAD; n°: 40). The patients were compared with
54 community dwelling non-demented older controls.
Results: After adjustment for functional status, blood sedimentation rate, and serum albumin
levels, no differences in lipoprotein profile emerged between the three groups, with the exception
of HDL-C that was lower in VD compared with controls. Low HDL-C (< 45 mg/dL) was associated
with VD (O.R.: 6.52, C.I. 95%: 1.42–30.70 vs controls, and 4.31, C.I. 95%: 0.93–19.82 vs LOAD),
after multivariate adjustment. No differences in plasma lipid levels emerged between the three
groups after stratification for apo E4 genotype.
Conclusions: In this cross-sectional study low HDL-C levels are associated with VD, but not with
LOAD, in a sample of older subjects.
Background
Some alterations of lipoprotein profile, such as hypercho-
lesterolemia and reduced levels of high-density lipopro-
tein cholesterol (HDL-C), are considered risk factors for
cardiovascular disease, and pheraps for cerebro vascular
disease [1–3].
In the last few years several authors have investigated the
possible role of dyslipidemias in the pathogenesis of vas-
cular dementia (VD) and Alzheimer's disease (AD); in-
deed, it has been recently suggested that cerebrovascular
disease might play a role not only in VD but also in deter-
mining the presence and severity of AD [4].
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Reduced HDL-C [5,6] and apo A-I levels [7], as well as in-
creased levels of lipoprotein (a) [7–9] have been reported
in VD by some authors, but not by others [9,10]; further-
more, dementia "with stroke" has been associated with
high levels of total (TC) and low-density lipoprotein
(LDL) cholesterol in a large longitudinal survey [9]. Con-
flicting results have been obtained in AD: indeed, both in-
creased and reduced TC values [11–13], HDL-C levels
[7,14,15], and LDL-C levels [11,15] have been reported in
different studies. High Lp(a) values have also been found
in AD patients [16].
On the whole, the possible association of dyslipidemias
with VD or AD is still a controversial issue, probably due
to: 1) the very small number of patients included in most
of the studies, and 2) the exclusion from the analysis of
some important factors that might induce significant
modifications in lipoprotein profile. As regards to this as-
pect, several conditions are known to modify plasma lip-
ids in the elderly including age itself, gender, apoprotein
E phenotype [17], impaired functional status [18], a con-
dition of "frailty" [19], and an inflammation state [20].
In the present study we investigated the lipoprotein pro-
file in a sample of older patients with VD or AD, and com-
pared them with a group of older non-demented controls,




Three groups of subjects were enrolled in the present
study:
1. Sixty consecutive patients with "probable" vascular de-
mentia by the NINDS-AIREN criteria [21]. All subjects had
an Hachinski ischemic score over 7 [22]. By CT scan,
fourty subjects (66.6%) had small-vessel disease, 14
(23.4%) subjects had large-vessel disease, and 6 (10%)
had both small and large vessel disease.
2. Fourty consecutive patients with "probable" late-onset
Alzheimer's disease (LOAD) by the NINCDS-ADRDA cri-
teria [23].
The diagnosis of VD and LOAD was made by trained ger-
iatricians; for neuropsychological assessment all subjects
were given a battery of standardized tests.
3. Fifty four community dwelling older subjects without
dementia. These subjects had a negative history for cardi-
ovascular and thyroid disease, renal or hepatic insufficien-
cy, and chronic inflammatory diseases. They did not
follow an hypolipemic diet.
No patients with VD and LOAD, or control subjects were
treated with lipid lowering drugs.
Plasma lipids
Blood samples were obtained after 12 hour overnight fast-
ing, kept at 4°C for 1 h, and centrifuged at 3000 rpm for
10 m' at 4°C to obtain serum or plasma. Total cholesterol
(TC) and triglycerides (TG) were assayed by the Trinder
method. HDL-C was determined after selective precipita-
tion of apoprotein B-containing lipoproteins with MgCl2-
phosphotungstic acid. Apoproteins A-I and B were meas-
ured by nephelometry. Low-density lipoprotein cholester-
ol (LDL-C) was calculated by the Friedewald equation
(LDL-C: TC – TG/5 – HDL-C). Lipoprotein (a) was meas-
ured by ELISA (kit Immunozym Lp(a), Immuno, GMBH).
Apo E genotype was evaluated on genomic DNA by
polymerase chain reaction by the method of Hixon & Ver-
nier.
Clinical chemistry
Serum albumin was measured by nephelometry. Blood
sedimentation rate (BSR) was determined by the Win-
trobe method. BSR is typically increased during acute
phase; although it is not an absolutely specific marker, it
is currently utilized in literature as an acute phase indica-
tor [24].
Functional status
Basic activities of daily living (BADLs) were measured by
the Barthel index [25] with a score ranging from 0 (severe
disability) to 20 (no disability).
Statistical analysis
Data are reported as mean ± standard error (SE) or stand-
ard deviation (SD) as reported. Due to the "skewed" dis-
tribution of values, Lp(a) was expressed as median
(range). The χ 2 test was used to compare the categorical
variables. Means were compared by ANOVA. ANCOVA
was used to compare lipoprotein parameters including
Barthel index score, blood sedimentation rate, and serum
albumin levels as covariate. Lp(a) levels were compared
by the Kruskal-Wallis test.
The odds ratio (VD vs LOAD, VD vs C, and LOAD vs C)
was calculated by multivariate logistic regression analysis.
HDL-C was transformed into a categorical variable (cut-
off: 45 mg/dL); albumin, BSR, and Barthel score were in-
cluded as confounders.
Systat for Windows version 5.0, and SPSS for Windows
version 7.0 statistical packages were used.
Results
The principal characteristics of the three groups are report-
ed in table 1. No differences emerged in age and genderBMC Geriatrics 2001, 1 http://www.biomedcentral.com/1471-2318/1/5
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distribution. As expected, subjects with VD and LOAD
had lower MMSE and Barthel index score compared with
controls, while no differences were found between VD
and LOAD. Serum albumin was lower in VD compared
with controls (p: 0.01); BSR was higher in both VD and
LOAD compared with controls (p: 0.04). Unadjusted li-
poprotein parameters are compared in table 2. Total and
LDL cholesterol were lower in VD compared with controls
(p: 0.001), while HDL-C was lower in VD compared with
both LOAD (p:0.04) and controls (p: 0.001).
The prevalence of the ε 4 allele was 13.3% in VD, 17.5% in
LOAD, and 9.2% in controls; the results reported in table
2 didn't change after stratification for the presence/ab-
sence of ε 4 allele (data not shown).
In table 3, the lipoprotein parameters are compared after
adjustment for Barthel score, blood sedimentation rate,
and serum albumin levels. No differences emerged be-
tween the three groups, with the exception of the HDL-C
that was significantly lower in VD compared with controls
(p: 0.04).
Low HDL-C (< 45 mg/dL) was associated with VD: the
odds ratio was 6.52 (C.I. 95%: 1.42–30.70) compared
with controls, and 4.31 (C.I. 95%: 0.93–19.82) compared
with LOAD, after adjustment for albumin, BSR, and Bar-
thel score. The odds ratio for LOAD was 1.13 (C.I. 95%:
0.24–6.26) compared with controls.
Discussion
The main result of this study is the finding of lower HDL-
C levels in patients with VD compared with controls, be-
fore and after adjustment for possible confounders.
The neglect of confounding factors is a major limitation
when comparing plasma lipids among groups of older
subjects; indeed, lipoprotein metabolism is influenced by
a number of conditions that are typical of the elderly pop-
ulation. Different studies reported lower lipid levels in
older subjects with comorbidity, disability, or with mark-
ers of acute phase [18,26,27,20]. Recently, Corti et al. [19]
suggested that the consideration of indicators of poor
health and markers of frailty, i.e. serum albumin and iron
levels, may help to clarify the role of cardiovascular risk
factors in various diseases in older subjects.
Our data are in good agreement the findings of other au-
thors. Kurijama et al. reported lower HDL-C levels in 43
VD patients compared with controls [5], while Katzman et
al. found lower HDL-C levels in older men with dementia
"with a vascular component" [28]. Munckle et al. found
lower HDL-C values in five VD compared with twelve
LOAD patients [6], and proposed a possible role of HDL-
C in the differential diagnosis of these two forms of de-
mentia; nevertheless, although HDL-C was slightly lower
in VD versus LOAD in our sample, it was not useful in dis-
criminating VD from LOAD.
It has not been established the possible mechanism link-
ing low HDL-C and VD. A first possibility is that low HDL-
C levels might be the result of the cross-sectional design of
this study and of the effect of dementia on plasma lipid
levels. We cannot exclude this possibility; nevertheless, if
this is the case we should not observe significant differenc-
es between VD and LOAD.
A second possibility is that low HDL-C levels might be in-
volved in the pathogenesis of VD. Many epidemiological
studies have found a negative association between HDL-C
levels and risk of ischemic stroke [29], but the pathogene-
sis of different subtypes of ischemic stroke may differ.
Most of our VD patients were affected by lacunar strokes,
and of consequence we might hypothesize a possible as-
sociation between low HDL-C values and small vessels
disease. It has been suggested that HDL particles might
Table 1: Principal characteristics of demented (VD and LOAD) and control subjects.
VD LOAD CONTROLS
Number 60 40 54
Age (years) 81.3 ± 0.8 79.1 ± 1.0 82.2 ± 0.8
Female gender 55% 68% 66%
MMSE 16.4 ± 0.7 14.8 ± 0.8 26.5 ± 0.6*
Barthel index 8.2 ± 0.7 10.9 ± 1.0 18.6 ± 0.7°
Serum albumin (mg/dL) 3.79 ± 0.5 4.01 ± 0.48 4.06 ± 0.5 ^
BSR (mm/1h) 32.6 ± 0.8 29.9 ± 0.7 17.8 ± 0.8 §
VD: vascular dementia; LOAD: late onset Alzheimer's disease MMSE: mini mental status examination; BSR: blood sedimentation rate * p: 0.002 C vs 
VD and LOAD; ° p: 0.001 C vs VD and LOAD ^ p: 0.01 C vs VD; § p: 0.04 C vs VD and LOADBMC Geriatrics 2001, 1 http://www.biomedcentral.com/1471-2318/1/5
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play a role in the removal of excess cholesterol from the
brain by interaction with apo E and heparan sulfate prote-
oglycans in the subendothelial space of cerebral microves-
sels [30]. It is also known that HDL particles favour
endothelium dependent vasorelaxation by inhibiting the
action of oxidized LDL particles [31], and interfere with
induction of endothelial cell adhesion molecules [32];
these mechanisms might be involved in the pathogenesis
of small vessels disease. Interestingly, Bonarek et al. re-
cently found that, in a nested case-control study, elevated
HDL-C levels were associated with a decreased risk of de-
mentia at multivariate analysis [33]; nevertheless, in their
sample the majority of subjects were affected by AD.
A second result of this study is the lack of significant dif-
ferences in lipoprotein parameters when comparing
LOAD patients and controls. In unadjusted analysis HDL-
C was higher in LOAD compared with VD, but this differ-
ence was no more significant after adjustment. Plasma li-
pids have been investigated in LOAD patients by several
authors in the last few years, but on the whole the results
are controversial. Our data seem to confirm the findings
of some authors which found no differences in TC and
LDL-C [9,14,34], nor in HDL-C [9,34] levels between
LOAD and controls.
Conclusions
In this cross-sectional study we found that older subjects
with VD, are characterized by lower HDL-C levels com-
pared with controls. Longitudinal studies are needed in
order to elucidate the possible role of HDL particles in the
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